Franklin Biotechnology One Year Return vs. Equity Positions Weight
| FBTDX Fund | USD 123.65 2.44 2.01% |
For Franklin Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Franklin Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Franklin Biotechnology Discovery utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Franklin Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Franklin Biotechnology Discovery over time as well as its relative position and ranking within its peers.
Franklin |
Franklin Biotechnology Equity Positions Weight vs. One Year Return Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Franklin Biotechnology's current stock value. Our valuation model uses many indicators to compare Franklin Biotechnology value to that of its competitors to determine the firm's financial worth. Franklin Biotechnology Discovery is one of the top funds in one year return among similar funds. It is one of the top funds in equity positions weight among similar funds making about 6.00 of Equity Positions Weight per One Year Return. Comparative valuation analysis is a catch-all model that can be used if you cannot value Franklin Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Franklin Biotechnology's Mutual Fund. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Franklin Biotechnology's earnings, one of the primary drivers of an investment's value.Franklin Equity Positions Weight vs. One Year Return
One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
Franklin Biotechnology |
| = | 16.47 % |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
Franklin Biotechnology |
| = | 98.75 % |
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
Franklin Equity Positions Weight Comparison
Franklin Biotechnology is currently under evaluation in equity positions weight among similar funds.
Franklin Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Franklin Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Franklin Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Franklin Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Franklin Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.
Franklin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Franklin Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Franklin Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Franklin Biotechnology's important profitability drivers and their relationship over time.
Use Franklin Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Franklin Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Franklin Biotechnology will appreciate offsetting losses from the drop in the long position's value.Franklin Biotechnology Pair Trading
Franklin Biotechnology Discovery Pair Trading Analysis
The ability to find closely correlated positions to Franklin Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Franklin Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Franklin Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Franklin Biotechnology Discovery to buy it.
The correlation of Franklin Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Franklin Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Franklin Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Franklin Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Franklin Biotechnology position
In addition to having Franklin Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. Note that the Franklin Biotechnology information on this page should be used as a complementary analysis to other Franklin Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
To fully project Franklin Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Franklin Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Franklin Biotechnology's income statement, its balance sheet, and the statement of cash flows.